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Background: Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common cutaneous T-
cell lymphomas. MF/SS is accompanied by considerable morbidity from pain, itching and 
disfigurement.  
 
Aim: To identify factors associated with poorer health-related quality of life (HRQoL) in newly 
diagnosed MF/SS patients. 
 
Methods: Patients enrolled into PROCLIPI (an international observational study in MF/SS) had HRQoL 
assessed using the Skindex-29 questionnaire. Skindex-29 scores were analysed in relation to patient-
specific and disease-specific characteristics. 
 
Results: The study population consisted of 237 patients (60.3% male) with a median age of 60 years 
(IQR 49-70yrs), of whom 179 had early MF and 58 had advanced MF/SS. In univariate analysis, 
HRQoL as measured by Skindex-29 was worse in females, SS, late-stage MF, those with elevated 
LDH, alopecia, high mSWAT and confluent erythema.  Linear regression models only identified 
female gender (=8.61, p=0.003) and alopecia (=9.71, p=0.02) as independent predictors for worse 
global HRQoL. In item-level analysis showed that the severe impairment in symptoms (OR 2.14, 95% 
CI 1.19-3.89) and emotions (OR 1.88, 95% CI 1.09-3.27) subscale scores seen in female patients was 
caused by more burning/stinging, pruritus, irritation and greater feelings of depression, shame, 
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Conclusion: HRQoL is significantly more impaired in newly diagnosed female patients with MF/SS 
and in those with alopecia. As Skindex-29 does not include existential questions on cancer which 
may cause additional worry and distress, a comprehensive validated CTCL specific questionnaire is 
urgently needed to more accurately assess disease-specific HRQoL among these patients.   
 
What is already known about this topic? 
 Cross-sectional studies of mixed populations of known and newly diagnosed MF/SS patients 
have shown significant impairment of HRQoL. 
 Previous studies on assessing gender-specific differences in HRQoL in MF/SS are conflicting. 
 More advanced stage disease and pruritus is associated with poorer HRQoL in MF/SS. 
 
What does this study add? 
 This is the first prospective study investigating HRQoL in a homogenous group of only newly 
diagnosed MF/SS patients. 
 In newly diagnosed MF/SS patients, HRQoL in is worse females and in those with alopecia 
and confluent erythema. 
 MF/SS diagnosis has a multi-dimensional impact on patient HRQoL including a large burden 
of cutaneous symptoms as well as negative impact on the emotional well-being. 
 
Introduction  
Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of non-Hodgkin lymphomas 
characterized by skin homing T-cells.  Mycosis fungoides (MF) is the most common subtype of CTCL 
(54-72% of all cases) and has an annual incidence 7.7 new cases per 1,000,000 person-years with a 
median age at diagnosis of 55-60 years and more commonly affects male patients (M:F = 2.1:1)1.   
Early-stage classical MF is characterized by erythematous, scaly patches or plaques involving photo-
protected limb girdle sites (so-called ‘bathing trunk’ distribution). Sézary syndrome (SS) representing 
3% of CTCLs, is an aggressive leukaemic form of cutaneous lymphoma typically characterized by 
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The 2007 revised staging system of MF/SS classify disease presentation based on skin (T), lymph 
node (N), visceral (M) and blood (B) involvement4.  Early-stage disease (IA to IIA) carries a good 
prognosis with a median survival of 12.9 years, in contrast to late-stage disease (IIB to IVB) which 
carries a worse prognosis5.  The predicted 5-year overall survival (OS) rates are 57.4% for stage IIB, 
58.2% for stage III, 42.9% for stage IVA, and 39% for stage IVB. Stage IV disease, age >60 years, large 
cell transformation (LCT; presence of large cells exceeding 25% of the total lymphoid infiltrate) and 
elevated serum lactate dehydrogenase (LDH) are independent prognostic factors for worse survival6.   
 
Quality of life (QoL) is a broad concept incorporating all aspects of an individual’s existence, while 
health-related quality of life (HRQoL) is a subset of QoL that relates more specifically to the effects 
health/illness(es)7. While QoL and HRQoL are used interchangeably and synonymously in the 
literature, both aim to capture patient health and well-being8.  Previous studies  have found  HRQoL 
is significantly impaired in CTCL however it is not routinely assessed in daily clinical practice and 
hence treating physicians may be unaware of patients at risk for social isolation and depression.  The 
PROCLIPI (Prospective Cutaneous Lymphoma International Prognostic Index) study9 provides a 
unique platform to study HRQoL in patients with MF/SS.   
 
The aim of this observational multicentre study was to evaluate the effects of skin disease on HRQoL 




The PROCLIPI study prospectively collects clinical, pathological, genotypic, treatment and HRQoL 
data on MF/SS from worldwide sites9.  All newly diagnosed patients with MF/SS are eligible for study 
participation within 6 months of a multidisciplinary confirmed diagnosis. The datasets collected at 
baseline and stage progression are shown in Figure S1 (Supplementary Data). HRQoL was captured 
using the Skindex-29 questionnaire.  The study was approved by the local Institutional Review 
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Skindex-29 Questionnaire 
HRQoL data were recorded on paper using the Skindex-29 questionnaire (permission granted by 
MAPI Research Trust, Lyon, France, November 2014)11 in the native language of the patient and 
subsequently uploaded to the PROCLIPI database.  For this work, only Skindex-29 questionnaires at 
diagnosis (visit 1) were included.   
 
The Skindex-29 questionnaire is a 30-item questionnaire refined from the original 61 item version of 
the Skindex dermatologic HRQoL instrument10 with one item (item 18) excluded from scoring12.  The 
29 items deal with various aspects of HRQoL including 7 subscale items relating physical symptoms, 
10 relating to emotional aspects of the disease and 12 relating to psychosocial functioning.  Each 
statement in the Skindex-29 questionnaire was scored on a 5-point Likert scale 
(points;never=1,rarely=2,sometimes=3,often=4,all-the-time=5). Participant’s answers were 
converted into linear scale scores between 0 (no effect) to 100 (maximum effect), with higher scale 
scores indicating a lower HRQoL10. The respondent's overall HRQoL was expressed as a global 
Skindex-29 score by computing the mean of the points from each subscale13.  Global Skindex-29 
scores were excluded if >25% of items were missing.   
 
 
Statistical Analysis  
Data was collated and analysed at Biostatistical Department, University Hospital Birmingham, UK.  
Normality of distribution was verified using the Shapiro-Wilk test. Univariate analyses were 
performed between Skindex-29 median scores and groups of patients according to patient 
characteristics (age, gender, ECOG) and disease characteristics (MF/SS, EORTC classification, early vs 
late-stage, TNMB stage, disease stage, raised LDH and clinical features including alopecia, confluent 
erythema, hypopigmentation, ulceration and follicular MF lesions).  The Mann-Whitney U-test and 
Kruskal-Wallis test (followed by Bonferroni correction for multiple comparisons) was used to analyze 
continuous variables and are presented as medians and interquartile ranges (IQR).  The power and 
direction of the relationships between age, mSWAT and Skindex-29 scores was determined using the 
non-parametric Spearman's rank-order correlation.  The association between categorical variables 
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Multiple linear regression analysis was completed using Skindex-29 scores as the dependent variable 
whereas independent variables collected at the same timepoint included demographic data (age and 
gender), diagnosis of MF/SS, early (IA-IIA)/late-stage disease (IIB-IVB), alopecia and confluent 
erythema.  In addition, the role of each aforementioned independent variables on HRQoL were 
evaluated in a logistic regression model on the basis of Skinex-29 score dichotomized as severe or 
non-severe HRQoL impairment as the dependent variable.   The cut-off scores for severe HRQoL 
impairment defined by Prinsen et al for global Skindex-29 score was 44 and for symptoms, 52 
emotions, 39  and functioning, 3714.   
 
To further explore specific items in the Skindex-29 questionnaire relating to worse HRQoL, an item-
level analysis was conducted using ordinal regression analysis15.  Association between age, gender, 
MF/SS, early/late-stage disease, alopecia and confluent erythema in determining item responses 
were evaluated based on the Skindex-29 questionnaire likert scale.  Results are reported as odds 
ratio (OR) and 95% confidence intervals (CI). 
 
All analyses were carried out using R version 3.2.4 with a level of significance set at p < 0.05.   
 
Results  
From July’15-Dec’18, Skindex-29 scores in 238 patients from 25 specialist centres spanning 4 
continents (UK, n=110; Belgium, n=20; Austria, n=18; Greece, n=13; France, n=11; Spain, n=11; Italy, 
n=10; USA, n=9; Finland, n=8; Australia, n=8; Germany, n=8; Switzerland, n=6; Hungary, n=3 and  
Brazil, n=2) (Table 1) were collected. Of the 238 patient questionnaires, n=207 (86.97%) were 100% 
complete, while n=21 (8.82%) had only one missing response.  Five patients (2.1%) had two missing 
responses and four patients (1.68%) had three missing responses while one was excluded from final 
analysis due to 10 missing responses.  In our final study population (n=237), the median age was 60 
years (IQR 49-70) with a male to female ratio of 1.5:1.  A total of 211 (89.03%) patients had MF 
(early-stage, n=178;  late-stage, n=33) and 26 (10.97%) had SS. The male to female ratio was 1.58:1 
in early-stage MF and 1.36:1 in late-stage MF/SS (χ2 test, p=0.62). The median global Skindex-29 
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Variables associated with worse HRQoL in patients with MF/SS 
No correlation between global Skindex-29 score and patient age (p=0.83) or ECOG performance 
status (p=0.23) was observed (Table 3).  Female patients had significantly worse HRQoL (p=0.02) 
with higher median (IQR) global Skindex-29 scores [34.19 (IQR 20.69-52.84)] compared to male 
patients [27.62 (IQR 13.73-44.87)].  A corresponding gender disparity in QoL was observed in both 
symptoms (p=0.01) and emotions (p=0.02) but not in functioning subscales (p=0.12).   
HRQoL correlated with extent of skin disease as measured by mSWAT score (P<0.0001, Table 3) and 
T stage.  Interestingly, the extent of blood involvement but not nodal or visceral involvement was 
significantly associated with impaired overall HRQoL (Supplementary data, Table S1).  When patients 
were stratified according to MF/SS diagnosis, patients diagnosed with SS had significantly more 
impaired overall HRQoL (p=0.001) in all subscale domains compared to MF. Given that more 
advanced disease is associated with a greater burden of symptoms HRQoL was evaluated in patients 
with early (IA-IIA) and late stages (IIB-IVB).  Patients with late-stage disease had worse overall HRQoL 
(p=0.002), more symptoms (p=0.0002) and functional impairment (p=0.002) in contrast to those 
with early-stage disease.  As more advanced disease is characterized by a greater burden of 
cutaneous and extra-cutaneous disease, the impact of serum LDH on HRQoL was examined.  Global 
Skindex-29 scores were more significantly impaired in patients with elevated LDH (p=0.001) 
compared to those with normal levels.  This was also true for symptoms and functioning subscale 
scores whereas a non-significant trend in emotional subscale scores (p=0.05) in patients with a 
raised LDH was observed.   
 
Examination of clinical features in patients with MF/SS demonstrated that patients with alopecia had 
worse global (p=0.004), emotional (p=0.001) and functioning (p=0.03) subscale scores but not 
symptoms (p=0.05) scores compared to those without alopecia.  Patients with confluent erythema 
had worse overall HRQoL but no differences in emotional subscale scores were found.  In those with 
confluent erythema there was a moderate correlation between mSWAT and symptom subscale 
scores (rs=0.53; 95% CI 0.20-0.75, p=0.002) but only a weak correlation with global and functioning 
subscale scores (Supplementary file, Table S1).   No significant difference in HRQoL was observed in 
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Independent Factors Associated with Worse HRQoL  
To determine which parameters were independently associated with worse HRQoL in MF/SS, a 
number of candidate covariates were computed in multivariate linear regression models using 
Skindex-29 scores as the dependent variable.  Independent factors associated with worse global 
Skindex-29 scores included female gender [=8.61 (95% CI, 2.89-14.09); p=0.003], alopecia [=9.71 
(95% CI, 1.63-17.44); p=0.02] and confluent erythema [=8.13 (95% CI, -0.02-16.06); p=0.05].  
Female gender and confluent erythema had a significant relationship with worse symptoms and 
functioning, whereas only a diagnosis of alopecia was related to overall impairment of emotions 
[=12.7 (95% CI, 3.56- 21.42); p=0.01] (Table 4).    
 
In a logistic model using severe impairment of HRQoL (global, symptoms, emotions and functioning 
cut-offs were 44,  52, 39 and  37) as the dependent variable, female gender was associated 
with severe impairment in symptoms (OR 2.14, 95% CI 1.19-3.89, p=0.01) and emotions (OR 1.88, 
95% CI 1.09-3.27, p=0.02) subscale scores.  Confluent erythema was associated with severe 
impairment of symptoms (OR 2.8, 95% CI 1.26-6.24, p=0.01) and alopecia with the emotional 
subscale (OR 2.57, 95% CI 1.18-5.79 p=0.02) [Supplementary file, Table S2]. 
 
Item-analysis of Skindex-29 questionnaire in MF/SS 
An item-level analysis on the Skindex-29 responses was used to identify which answers varied by 
patient characteristics.  Of particular interest were gender specific differences in item responses but 
also variables such as alopecia, confluent erythema and late-stage disease were assessed.  Items on 
the Skindex-29 questionnaire which were more likely to be scored higher in female patients included 
subscale questions related to symptoms: burning/stinging, itching, water bothering the skin during 
bathing/washing, irritation and sensitivity; emotions: depression, shame, embarrassment, 
annoyance; and functioning: impaired sleep. (Figure 1).  Patients with alopecia were more likely to 
score higher in Skindex-29 items relating to emotions, while patients with confluent erythema were 
more likely to score higher in questions related to symptoms and functioning.  Only one question 
was significantly more likely in patients with late-stage disease (“my skin condition bleeds”) 
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Discussion  
This is the largest international study to evaluate HRQoL in newly diagnosed MF/SS patients and 
relating this to patient demographics and physician-reported disease characteristics at the same 
timepoint. HRQoL was measured using Skindex-29 questionnaire which adequately covers skin 
disease symptoms but does not include cancer related items. HRQoL in patients with MF/SS was 
significantly worse in female patients, SS, late-stage MF and those with a raised serum LDH, alopecia 
and confluent erythema.  Both alopecia and confluent erythema are visual clinical features which 
may impact on a patient’s wellbeing. However, in multivariate models only female gender and 
alopecia were significantly associated with worse global HRQoL.  This study highlights the 
collaborative strength of the PROCLIPI study to provide a unique and meaningful insight into the 
impact of MF/SS on the lives of affected patients.   
 
There is no standardized approach for the interpretation of Skindex-29 scores. Both distribution-
based16 and anchor-based methods14 have been used to categorize Skindex-29 scores into mild, 
moderate and severe. It is generally agreed that an anchor-based approach is the optimal way to 
determine the minimally important difference (MID) in patient-reported outcomes17.  Prinsen et al. 
suggest the cut-offs for mild, moderate, and severe impairment of the global Skindex-29 score to be 
25,  32 and 44, respectively14.  The overall median (IQR) Skindex-29 score reported in our study 
of 29.75 (15.44 - 47.21) indicates that a diagnosis of MF/SS conveys a mild to moderate impact on 
overall HRQoL. This is comparable to acne vulgaris, atopic dermatitis, contact dermatitis and 
psoriasis13.  Interestingly, the results of our study show that in those with a diagnosis of SS their 
HRQoL scores are in the severe range [median (IQR) global Skindex-29 score, [50.58 (27.21 - 69.53)] 
and is much higher than benign dermatoses and non-melanoma skin cancer13,14.  Importantly, all 
aspects of HRQoL have been shown to be impaired in patients diagnosed with SS, 58% of whom 
report pruritus compared with 14% of patients with MF18.  In logistic regression analysis however, 
only female gender and confluent erythema were independently associated with worse HRQoL on 
the symptom subscale indicating a diagnosis of SS alone does not fully explain impaired HRQoL in 
MF/SS.   
 
In accordance with this finding, we have shown both in univariate and multivariate analysis that 
female patients with MF/SS had significantly worse HRQoL compared to male patients.  Our 
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reported no gender specific difference in illness perception, but this might have been due to the 
male predominance within this cohort20. Female patients perceive their disease as more chronic and 
tend to be more emotionally affected than men19.  We found that female patients have more severe 
symptoms and are more emotionally affected than men.  No overall gender differences in 
functioning were observed, however the negative impact on sleep observed in female patients may 
reflect psychological stress.  Poorer HRQoL in female patients has been reported both in 
inflammatory skin diseases such as psoriasis21, atopic dermatitis22, vitiligo23 and also observed in 
survivors of non-Hodgkin’s lymphoma24.   
 
Our item-analysis of Skindex-29 responses provides insight into those aspects of the disease which 
are uniquely troublesome for female patients.  These included symptoms such as itching, stinging 
and burning, increased sensitivity and irritation as well as emotional aspects such as shame and 
embarrassment. Itching is frequently reported by CTCL patients and may be refractory to anti-
pruritic medication. Previous studies have shown correlation between pruritus severity score and 
total Skindex-29 score25 emphasizing itch as a troublesome symptom26. Patients with MF/SS 
experience a large number of disease related symptoms including pruritus, bleeding, flaking and red 
skin and an emotional burden of self-consciousness, restricted physical intimacy, anxiety and 
depression27,28.   
 
Alopecia was an independent prognostic variable for poorer HRQoL and was present in 14.8% (n=35) 
of patients in our study, higher than previously reported rates of 2.5% in patients with MF/SS.  The 
most common patterns of MF/SS related alopecia are areata-like patchy loss (33%) and alopecia 
within MF lesions (67%)29.  In our observations, alopecia was associated with worse global and 
symptoms subscale scores and with severe impairment in the emotions subscale score.  These 
findings were substantiated in item analysis showing higher responses that included shame, worry, 
anger and frustration.  The alopecia related global impairment in HRQoL observed in this study 
[37.44 (28.44 - 57.09)] is similar to alopecia areata (AA) and androgenetic alopecia (AGA) but results 
in greater emotional impairment [50 (35 - 65)] than either of the two latter diagnoses (AA: 44.6, 
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Similar to previously published data, we have shown that patients with more advanced skin disease 
(by mSWAT score and by T-stage) have worse HRQoL31. A correlation between mSWAT and overall 
HRQoL represents a noteworthy finding and this relationship is strengthened in those with confluent 
erythema indicating that a high burden of skin disease is inextricably linked to worse HRQoL.  In 
ordinal regression analysis of Skindex-29 responses, confluent erythema was associated with more 
pruritus, irritation and skin sensitivity and resulted in greater functional impairment due to sleep 
disturbance and difficulty in showing affection. This finding is similar to that observed in patients 
with psoriasis in whom more extensive disease and specific anatomical involvement experience a 
greater difficulty with physical intimacy32. 
 
PROCLIPI provides a unique platform to enhance our understanding of HRQoL in MF/SS patients, in 
particular by eliminating the single-centre/country bias in previous large studies.  It is plausible that 
a number of limitations may have influenced the results obtained.  Firstly, the number of other 
previously diagnosed medical and psychiatric co-morbidities is not recorded. A recent study found 
psychiatric condition and medical co-morbidities were significantly related to symptoms33. Secondly, 
the Skindex-29 instrument is a skin disease specific questionnaire and does not contain specific 
questions relating to cancer. Thirdly, as our study involved newly diagnosed patients, we did not 
examine the effect of treatment on HRQoL in MF/SS.  Systemic therapies may adversely affect 
HRQoL and therefore future studies to examine the impact of systemic treatment on HRQoL is 
important especially if patients with MF/SS have a stronger belief in treatment control19. This work 
has highlighted the need to develop a composite MF/SS specific questionnaire which simultaneously 
examines the effect of both skin disease and cancer diagnosis on HRQoL. A specific MF/SS-CTCL QoL 
instrument to capture patient HRQoL was recently developed and represents a pivotal step in the 
right direction to provide more patient-tailored supportive care. However, the sample of patients 
who participated in this study were largely of those with stage I disease, thus under-representing 
those with more advanced stages34. 
 
In conclusion, this study has highlighted important patient-specific and disease-specific features 
which impact HRQoL in MF/SS patients.  Even though male patients may have an overall worse 
prognosis1 it is interesting to note an overall worse HRQoL in females. Patients with alopecia and 
more extensive cutaneous disease experienced worse overall HRQoL with greater emotional, 
symptomatic and functional impairment. This is highly relevant as treatments in MF/SS rarely result 
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continuously suffer cutaneous disease.  Living with a cancer diagnosis and fear of dying can also 
significantly affect HRQoL. In-depth in-person qualitative interviews may assist in the development 
of a CTCL specific HRQoL questionnaire that encompasses both early and late-stage disease to 
enable us to fully understand the impact of HRQoL in MF/SS. 
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Table 1.  Participating International Centres 
 
Centre No.  Principal Investigator Address  No. Patients 
E001 Julia Scarisbrick University Hospitals Birmingham, UK 62 
E047 Anne Marie Busschots University Hospitals Leuven, Belgium 20 
E012 Constanze Jonak  Medical University of Vienna, Austria  18 
E006 Richard Cowan Christie Hospital, Manchester, UK 17 
E007 Evangelina Papadavid Athens University Medical School, Greece 13 
E022 Marie Beylot-Barry Centre Hospitalier Universitaire Hospital de Bordeaux, France 11 
E024 Emilio Berti Department of Dermatology, Fondazione Ca’ Granda, IRCCS, OMP, Milano, Italy 10 
E023 Teresa Estrach Hospital Clinico, University of Barcelona, Spain 9 
E028 Rubeta Matin Churchill Hospital, Oxford, UK 9 
E063 Oleg Akilov University of Pittsburgh School of Medicine, Pennsylvania, USA 9 
E017 Liisa Vakeva Helsinki University Central Hospital, Finland 8 
E056 Miles Prince Peter Maccallum Cancer Centre, Melbourne, Australia 8 
E031 Andrew Bates University Hospital Southampton, UK 7 
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E032 Mike Bayne Poole Hospital, Dorset, UK 5 
E036 Rachel Wachsmuch Royal Devon & Exeter Hospital, UK 5 
E046 Ulrike Wehkamp University Hospital Kiel, Germany 5 
E045 Marta Marschalko Semmelweis University, Budapest, Hungary 3 
E019 Octavio Servitje Hospital Universatari de Bellvitge, Barcelona, Spain 2 
E034 Deborah Turner Torbay Hospital, UK 2 
E037 Sophie Weatherhead Newcastle Upon Tyne NHS Trust, UK 2 
E048 Marion Wobser University Hospital Wuerzburg, Germany 2 
E059 José Antonio Sanches University of Sao Paulo Medical School, Brazil, South America 2 
E039 Pam McKay Beatson West of Scotland Cancer Centre, Glasgow, Scotland 1 
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Table 2.  Demographics and Baseline Characteristics of Study Population (n = 237) 
 
Patient Characteristics 
Characteristic Value n (%), unless stated otherwise 
Agea Median (IQR) 60 (49 - 70) 
Gender Male 143 (60.34) 
Female 94 (39.66) 
ECOG 0 214 (90.3) 
1 15 (6.33) 
2 6 (2.53) 
3 2 (0.84) 
Skindex-29 Scorea Global  29.75 (15.44 - 47.21) 
Symptoms 39.29 (21.43 - 57.14) 
Emotions 35 (20 - 55) 
Functioning 12.5 (4.167 - 33.85) 
Disease Characteristics 
Characteristic Value n (%), unless stated otherwise 
mSWAT Scorea - 20 (6.6 – 54.8) 
MF/SS Mycosis Fungoides 211 (89.03) 
Sézary Syndrome 26 (10.97) 
Disease Stage IA 94 (39.66) 
IB 72 (30.38) 
IIA 16 (6.75) 
IIB 18 (7.59) 
IIIA 5 (2.11) 
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IV (A1) 14 (5.91) 
IV (A2) 7 (2.95) 
IVB 2 (0.84) 
Early vs Late-stage Early 179 (75.53) 
Late 58 (24.47) 
Raised LDH - 53 (22.36) 
Alopecia - 35 (14.77) 
Confluent erythema - 54 (22.78) 
Hypopigmentation - 14 (5.91) 
Ulceration - 15 (6.33) 
Follicular MF Lesions - 45 (18.99) 
 
Notes 
a Values quoted as median + (IQR, interquartile range)  
Abbreviations: ECOG, Eastern Cooperative Oncology Group Performance status; mSWAT, modified 
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Table 3.  Variables associated with worse QoL in patients with MF/SS 
 
n 
Global Symptoms Emotions Functioning 
Value P-value Value P-value Value P-value Value P-value 
Agea - 237 -0.014 0.83 0.037 0.57 0.081 0.21 -0.0003 0.99 
ECOGb 0 214 30.24 (15.48 – 46.35) 
0.23 
39.29 (21.43 – 57.14) 
0.29 
35 (20 – 55) 
0.13 
12.5 (4.17 – 33.33) 
0.29 
1 15 25.65 (12.78 – 65) 35.71 (25 – 75) 25 (12.5 – 45) 10.42 (6.25 – 60.42) 
2 6 63.19 (19.43 – 80.87) 51.79 (43.75 – 77.68) 66.25 (11.3 – 87.5) 64.58 (3.13 – 80.21) 
3 2 17.27 (12 – 22.54) 30.36 (21.43 – 39.29) 16.25 (12.5 – 20) 5.2 (2.1 – 8.3) 
Gender Males 143 27.62 (13.73 - 44.87) 
0.02 
35.71 (17.86 - 53.57) 
0.01 
30 (17.5 - 52.5) 
0.02 
12.5 (2.08 - 29.69) 
0.12 
Females 94 34.19 (20.69 - 52.84) 42.86 (25 - 64.29) 40 (23.12 - 59.38) 15.62 (6.25 - 37.5) 
mSWATa - 237 0.3514 <0.0001 0.3812 <0.0001 0.263 <0.0001 0.3286 <0.0001 
MF/SS MF 211 28.46 (14.67 - 44.87) 
0.001 
35.71 (17.86 - 53.57) 
0.0003 
32.5 (19.38 - 52.5) 
0.05 
12.5 (2.08 - 29.17) 
0.001 
SS 26 50.58 (27.21 - 69.53) 55.36 (42.86 - 75) 45 (27.5 - 72.5) 40.63 (8.85 - 61.98) 
Disease Stage  Early 179 27.55 (14.67 - 42.43) 
0.002 
35.71 (17.86 - 53.57) 
0.0002 
32.5 (20 - 52.5) 
0.09 
12.5 (2.08 - 29.17) 
0.002 
Late 58 36.46 (21.94 - 65.83) 50 (35.71 - 71.43) 42.5 (20 - 71.25) 20.83 (8.33 - 59.9) 
Raised LDH No 184 27.48 (14.64 - 43.04) 
0.001 
35.71 (17.86 - 50) 
<0.0001 
32.5 (20 - 52.5) 
0.05 
12.5 (4.17 - 29.17) 
0.002 
Yes 53 36.35 (24.56 - 68.53) 53.57 (35.71 - 75) 40 (20 - 72.5) 22.92 (8.33 - 60.42) 
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Yes 35 37.44 (28.44 - 57.09) 42.86 (30.36 - 64.29) 50 (35 - 65) 22.92 (9.38 - 57.29) 
Confluent erythema No 183 26.37 (14.67 - 42.43) 
0.001 
35.71 (17.86 - 50.89) 
<0.0001 
32.5 (19.38 - 52.5) 
0.11 
10.42 (2.08 - 29.17) 
0.0007 
Yes 54 36.51 (26.3 - 64.33) 53.57 (36.61 - 70.54) 40 (22.5 - 65) 26.04 (8.85 - 57.81) 
Hypopigmentation No 223 29.8 (15.78 - 47.28) 
0.65 
39.29 (21.43 - 57.14) 
0.13 
35 (20 - 52.5) 
0.70 
12.5 (4.17 - 33.33) 
0.88 
Yes 15 26.53 (13.27 - 43.04) 25 (8.93 - 42.86) 42.5 (18.75 - 55) 12.5 (5.21 - 34.38) 
Ulceration No 222 29.7 (15.41 - 46.18) 
0.26 
39.29 (21.43 - 57.14) 
0.08 
35 (20 - 52.5) 
0.70 
12.5 (4.17 - 33.33) 
0.39 
Yes 15 34.84 (23.55 - 60.2) 46.43 (41.07 - 71.43) 35 (21.25 - 62.5) 14.58 (6.25 - 58.33) 
Follicular MF No 192 33.47 (29.31 - 95.48) 
0.73 
39.69 (39.29 - 96.43) 
0.81 
37.97 (32.5 - 100) 
0.54 
22.77 (12.5 - 100) 0.88 
0.99 Yes 45 35.42 (31.29 - 100) 41.59 (39.29 - 100) 40.56 (37.5 - 100) 24.12 (14.58 - 100) 
 
Notes: Results analysed using the Mann-Whitney U test unless otherwise indicated 
a
Analysed using the non-parametric Spearman's rank-order correlation 
b
Analysed using the Kruskal-Wallis test, with Bonferroni correction for multiple comparisons 
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Table 4.  Multiple linear regression analysis of factors influencing Skindex-29 scores in patients with MF/SS.   
 
Variable n 
Global Symptoms Emotions Functioning 
 SE P-value  SE P-value  SE P-value  SE P-value 
Age - -0.06 0.09 0.48 -0.04 0.09 0.67 -0.11 0.10 0.28 -0.04 0.10 0.71 
Female Gender 94 8.61 2.84 0.003** 9.95 3.07 0.001** 9.08 3.20 0.005** 6.80 3.17 0.03* 
Sézary Syndrome 26 6.65 5.89 0.26 6.44 6.36 0.31 4.30 6.65 0.52 9.21 6.57 0.16 
Late-stage Disease 58 4.87 4.21 0.25 5.24 4.55 0.25 4.53 4.76 0.34 4.83 4.70 0.31 
Alopecia 35 9.71 4.00 0.02* 8.43 4.32 0.05 12.70 4.52 0.01** 8.02 4.47 0.07 
Confluent Erythema 54 8.13 4.08 0.05 10.95 4.40 0.01** 3.66 4.60 0.43 9.77 4.55 0.03* 
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Figure 1.  Item-level analysis on the effect of female gender on Skindex-29 responses.  The main 
effect of gender on Skindex-29 responses was analysed using ordinal regression analysis by 
controlling for age, MF/SS, early/late-stage disease, alopecia and confluent erythema.  Results are 
adjusted odds ratio (OR) and 95% confidence interval (CI), where significance codes: * p<0.05; ** 
 
1.37 (0.85 - 2.21) 0.19
1.73 (1.07 - 2.80) 0.03
1.87 (1.16 - 3.04) 0.01
1.94 (1.18 - 3.19) 0.01
1.76 (1.10 - 2.84) 0.02
2.63 (1.63 - 4.28) 0.0001
1.40 (0.83 - 2.36) 0.20
1.31 (0.81 - 2.10) 0.27
1.81 (1.12 - 2.93) 0.02
1.59 (0.97 - 2.63) 0.07
1.98 (1.21 - 3.26) 0.01
1.61 (1.00 - 2.60) 0.05
1.28 (0.79 - 2.07) 0.32
2.16 (1.32 - 3.54) 0.002
1.44 (0.90 - 2.31) 0.13
1.59 (0.94 - 2.70) 0.09
1.65 (1.03 - 2.64) 0.04
2.02 (1.24 - 3.29) 0.005
1.59 (0.97 - 2.61) 0.07
1.59 (0.97 - 2.62) 0.07
1.49 (0.87 - 2.55) 0.14
1.45 (0.86 - 2.45) 0.16
1.60 (0.96 - 2.67) 0.07
1.31 (0.76 - 2.24) 0.33
1.50 (0.88 - 2.53) 0.13
0.86 (0.49 - 1.47) 0.57
1.14 (0.67 - 1.92) 0.63




































-0.5 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
My skin hurts –
My skin condition burns or stings –
My skin itches - Q
Water bothers my skin condition - Q
My skin is irritated - Q
My skin is sensitive - Q
My skin condition bleeds - Q
I worry my skin condition may be serious –
My skin made me feel depressed –
I worry about getting scars from skin condition –
I am ashamed of my skin condition – Q
I worry that skin condition might get worse – Q
I am angry about my skin condition – Q
I am embarrassed by my skin condition – Q
I am frustrated by my skin condition – Q
I am humiliated by my skin condition – Q
I am annoyed by my skin condition – Q
My skin affects how well I slept –
My skin makes it hard to work/do hobbies –
My skin affects my social life –
I tend to stay at home because of my skin –
My skin affects closeness with those I love – Q
I do things by myself because of my skin - Q
My skin makes showing affection difficult - Q
My skin  affects my interactions with others – Q
My skin is a problem for the people I love – Q
My skin  affects my desire to be with people – Q25
My skin interferes with my sex life– Q
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